Goodwin represented Albany Molecular Research, Inc. (NASDAQ:AMRI) in its agreement to be acquired by affiliates of The Carlyle Group and GTCR LLC for $21.75 per share in cash. This represents a 42% premium to the 60-day weighted average closing stock price leading up to April 5, 2017 (the last trading day prior to public rumors in the press regarding a potential sale process).
Closing of the transaction is subject to customary closing conditions. It is anticipated that the special meeting of AMRI’s stockholders to vote on the transaction will be held in the third quarter of 2017, and, if the transaction is approved, the merger would be expected to close shortly thereafter.
Albany Molecular Research Inc. is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades.
The Carlyle Group (NASDAQ:CG) is a global alternative asset manager with $162 billion of assets under management across 287 investment vehicles as of March 31, 2017. Carlyle’s purpose is to invest wisely and create value on behalf of its investors, many of whom are public pensions.
Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare, Technology, Media & Telecommunications and Growth Business Services industries. Since its inception, GTCR has invested more than $12 billion in over 200 companies.